Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
A report says Tesla has set a date for what it calls its riskiest launch yet. The challenge, according to the same coverage, may be less about picking a calendar day and more about what Tesla has to deliver afterward.
THE APEX TIMES
THE APEX TIMES
Market participants turned to NVIDIA shares alongside policy and earnings-adjacent catalysts, as new tariff headlines and Federal Reserve scrutiny set a cautious tone after a choppy prior week.
THE APEX TIMES
A high-profile lawsuit that began in U.S. court this month has raised fresh scrutiny of how Meta designs and markets its platforms, with one estimate of potential damages reaching an extraordinary scale.
THE APEX TIMES
The Danish drugmaker says it is partnering with AWS to modernize operations and apply artificial intelligence to research workflows, but key details on scope and timelines were not disclosed in the announcement cited by Yahoo Finance.
THE APEX TIMES
The Walt Disney Company has reached a multi-year deal to stream the all-electric Formula E World Championship across 144 territories, adding another live-sports property to Disney+ and potentially sharpening its pitch for viewers who expect live events.
THE APEX TIMES
Pfizer reported a modest year-over-year improvement in fiscal Q2 operations, indicating stabilization after the sharp contraction in pandemic-related demand. The market question now is whether the company’s pipeline and upcoming launches can offset the revenue pressure from an expected patent cliff.
THE APEX TIMES
A new proposal would resolve tens of thousands of lawsuits alleging Johnson & Johnson’s talc-based products contribute to ovarian cancer, but the broader pace of litigation and future claims remains the market focus.
THE APEX TIMES
A weekly market rally lost momentum as tariff headlines returned, while investors watched Nvidia and CrowdStrike and awaited Fed-related commentary tied to New York Fed President John Williams' successor-designate? (Warsh referenced by the market report).
THE APEX TIMES
A recent market piece on healthcare investing weighs J&J’s steady, diversified business against Thermo Fisher’s faster-linked growth from labs, clinical work, and manufacturing services, asking which pattern tends to hold up across cycles.
